Delivery of mGluR5 siRNAs by Iron Oxide Nanocages by Alternating Magnetic Fields for Blocking Proliferation of Metastatic Osteosarcoma Cells

Although osteosarcoma is the most common primary malignant bone tumor, chemotherapeutic drugs and treatment have failed to increase the five-year survival rate over the last three decades. We previously demonstrated that type 5 metabotropic glutamate receptor, mGluR5, is required to proliferate meta...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-07, Vol.23 (14), p.7944
Main Authors: Kang, Min A, Rao, Pooja P, Matsui, Hiroshi, Mahajan, Shahana S
Format: Article
Language:English
Subjects:
alternative magnetic field
Animals
Biomedical materials
Bone cancer
Bone Neoplasms - drug therapy
Bone Neoplasms - therapy
Bone tumors
Cancer therapies
Cell Line, Tumor
Cell Proliferation
Drug resistance
Efficiency
Ferric Compounds
Gene expression
Glutamic acid receptors (metabotropic)
Humans
iron oxide nanocages
Iron oxides
LM7
Magnetic Fields
Metastases
Metastasis
mGluR5 siRNA
Mice
Nanoparticles
OS482
Osteosarcoma
Osteosarcoma - drug therapy
Osteosarcoma - therapy
Osteosarcoma cells
RNA, Small Interfering - genetics
RNA, Small Interfering - therapeutic use
Sarcoma
siRNA
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although osteosarcoma is the most common primary malignant bone tumor, chemotherapeutic drugs and treatment have failed to increase the five-year survival rate over the last three decades. We previously demonstrated that type 5 metabotropic glutamate receptor, mGluR5, is required to proliferate metastatic osteosarcoma cells. In this work, we delivered mGluR5 siRNAs in vitro using superparamagnetic iron oxide nanocages (IO-nanocages) as delivery vehicles and applied alternating magnetic fields (AMFs) to improve mGluR5 siRNAs release. We observed functional outcomes when mGluR5 expression is silenced in human and mouse osteosarcoma cell lines. The results elucidated that the mGluR5 siRNAs were successfully delivered by IO-nanocages and their release was enhanced by AMFs, leading to mGluR5 silencing. Moreover, we observed that the proliferation of both human and mouse osteosarcoma cells decreased significantly when mGluR5 expression was silenced in the cells. This novel magnetic siRNA delivery methodology was capable of silencing mGluR5 expression significantly in osteosarcoma cell lines under the AMFs, and our data suggested that this method can be further used in future clinical applications in cancer therapy.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23147944